Aripiprazole Solution
Product Images NDC 70752-114

This is a description of Aripiprazole Oral Solution in a 150mL bottle. Each mL contains 1mg of aripiprazole in an aqueous solution. The oral solution comes with a tamper-evident seal and dosing cup enclosed. It is recommended to store between 20° to 25°C (68° to 77°F) with permitted excursions. Opened bottles can be used for up to 6 months after opening, but not beyond the expiration date. The medication guide should be given to each patient, and an electronic package insert is available online. The product is manufactured by Quagen Pharmaceuticals LLC in the USA.*

This is a description of Quagen Pharma's Aripiprazole Oral Solution, with each mL containing 1 mg of aripiprazole in an aqueous solution. The medication guide should be dispensed to each patient. The usual dosage instructions can be found in the package insert. The oral solution should be stored at 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F). Opened bottles can be used for up to 6 months after opening, but not beyond the expiration date. The product is manufactured by Quagen Pharmaceuticals LLC.*

This text details the effect of different drugs on the pharmacokinetics of Aripiprazole. It includes information on CYP3A4 inhibitors like ketoconazole, CYP2D6 inhibitors like quinidine, CYP3A4 inducers like carbamazepine, gastric acid blockers like famotidine, and other drugs such as valproate, lithium, and lorazepam. The reference value for Aripiprazole is given for comparison.*

This text discusses the effect of other drugs on Aripiprazole, focusing on the pharmacokinetic parameters influenced by various inhibitors, inducers, and blockers. Specifically, it looks at the impact on Aripiprazole's exposure levels (AUC) and maximum concentration (Cmax) when interacting with drugs such as CYP3A4 Inhibitors like ketoconazole, CYP2D6 Inhibitors such as quinidine, CYP3A4 Inducers like carbamazepine, Gastric Acid Blockers such as famotidine, and others like lithium and lorazepam. Additionally, it mentions the Fold Change in Dehydro-Aripiprazole and Relative Change compared to the reference levels when the interacting drugs are not involved.*

This text discusses the effect of Aripiprazole on other drugs, with a focus on their pharmacokinetics, including CYP2D6, INR, UGT1A4, and the AUC and Cmax values of a range of medications such as warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, 0-desmethylvenlafaxine, and escitalopram. It also presents data on fold change and 90% CI.*

This text presents information related to special populations with variations in CYP2D6 metabolism, gender, age groups, hepatic impairment levels, renal impairment, and pharmacokinetics parameters such as AUC and Cmax. The data also includes aripiprazole fold change and 90% confidence intervals for different values compared to a reference.*

This text appears to be a table outlining different comparisons related to PK (pharmacokinetics), including metabolizer status, gender, age, hepatic impairment, and renal impairment, along with dehydro-aripiprazole fold change and confidence intervals. It mentions categories such as poor vs. extensive metabolizer, female vs. male, age groups, mild/moderate/severe hepatic impairment, and severe renal impairment. Additionally, it seems to show comparison results relative to a reference.*

This is a data table showing the proportion with relapse for subjects on Aripiprazole compared to Placebo over a period of time since randomization. The numbers represent the number of subjects at risk over successive days.*

This is a table showing the number of subjects at risk for aripiprazole and placebo over different days from randomization. The data represents a study on relapse prevention. The number of subjects at risk in each group decreases over time, showing the progression of the study.*

This text provides information about the Least-Squares Mean Change in YGTSS Total TIC Score over 20 weeks of treatment, comparing the change in YGTSS Total TIC Score from baseline between ARP-LOW and ARIP-HIGH groups.*